Precision BioSciences (NASDAQ:DTIL - Get Free Report) is set to release its earnings data before the market opens on Monday, November 4th. Analysts expect Precision BioSciences to post earnings of ($0.79) per share for the quarter.
Precision BioSciences (NASDAQ:DTIL - Get Free Report) last issued its quarterly earnings results on Thursday, August 1st. The company reported $3.46 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.77) by $4.23. The firm had revenue of $49.90 million for the quarter, compared to the consensus estimate of $8.50 million. Precision BioSciences had a net margin of 19.36% and a negative return on equity of 7.64%. During the same quarter in the previous year, the company earned ($3.00) EPS. On average, analysts expect Precision BioSciences to post $1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Precision BioSciences Stock Down 1.1 %
DTIL stock traded down $0.09 during midday trading on Wednesday, reaching $8.07. 49,716 shares of the company's stock traded hands, compared to its average volume of 74,983. The company has a market cap of $58.38 million, a price-to-earnings ratio of 38.43 and a beta of 1.70. The firm's fifty day moving average price is $9.47 and its 200-day moving average price is $10.17. Precision BioSciences has a 52 week low of $8.01 and a 52 week high of $19.43.
Wall Street Analyst Weigh In
Separately, HC Wainwright reissued a "buy" rating and set a $60.00 price objective on shares of Precision BioSciences in a research note on Thursday, August 22nd.
Check Out Our Latest Analysis on Precision BioSciences
About Precision BioSciences
(
Get Free Report)
Precision BioSciences, Inc, an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA.
Featured Articles
Before you consider Precision BioSciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Precision BioSciences wasn't on the list.
While Precision BioSciences currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
